Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Jennifer A. Wargo"'
Publikováno v:
Cancer Immunology Research. 9:365-370
Several landmark preclinical studies have shown an association between the gut microbiota and the effectiveness of immunotherapy for cancer. These studies have sparked clinical trials aimed at modulating the gut microbiota in order to improve clinica
Autor:
Cheuk Hong Leung, Wayne L. Hofstetter, John V. Heymach, Alexandre Reuben, Myrna C.B. Godoy, Ara A. Vaporciyan, Padmanee Sharma, Yasir Elamin, Neda Kalhor, Robert R. Jenq, Junya Fujimoto, Tina Cascone, Anne S. Tsao, William N. William, Charles Lu, Frank E. Mott, Nadim J. Ajami, Don L. Gibbons, Jack A. Roth, David C. Rice, Luisa M. Solis, Hai T. Tran, Brett W. Carter, Lauren Averett Byers, Andrew Futreal, Lorenzo Federico, Annikka Weissferdt, Garrett L. Walsh, Reza J. Mehran, Chantale Bernatchez, George R. Blumenschein, Jennifer A. Wargo, Heather Lin, Cara Haymaker, Xiuning Le, Jonathan M. Kurie, Mehmet Altan, James P. Allison, Stephen G. Swisher, Edwin R. Parra, Boris Sepesi, Hitoshi Dejima, Frank V. Fossella, Jianjun Zhang, Bonnie S. Glisson, Mara B. Antonoff, Abdul Wadud Khan, Apar Pataer, Alejandro Francisco-Cruz, Ignacio I. Wistuba, Humam Kadara, J. Jack Lee, Ferdinandos Skoulidis
Publikováno v:
Nat Med
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 ran
Autor:
Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, Serigne Lo
Publikováno v:
Nature Medicine. 27:301-309
The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRA
Autor:
Jennifer A. Wargo, Giorgio Trinchieri, Kenya Honda, Romina S. Goldszmid, Laurence Zitvogel, B. Brett Finlay
Publikováno v:
Nature Reviews Immunology
There is currently much interest in defining how the microbiota shapes immune responses in the context of cancer. Various studies in both mice and humans have associated particular commensal species with better (or worse) outcomes in different cancer
Autor:
Asif Rashid, Phyu P. Aung, Doina Ivan, Jing Ning, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Victor G. Prieto, Richard E. Royal, Merrick I. Ross, Jeffrey E. Gershenwald, Michael A. Davies, Alexander J. Lazar, Laura E. Noordenbos, Jonathan L. Curry, Jin Piao, A. Hafeez Diwan, Michael T. Tetzlaff, Wei Lien Wang, Rashmi Samdani, Jennifer A. Wargo
Publikováno v:
Modern Pathology, 33(3), 496-513. Nature Publishing Group
Pathological staging of primary anorectal mucosal melanoma is often performed according to the American Joint Commission on Cancer (AJCC) guidelines for cutaneous melanoma, as an anorectal melanoma-specific staging system does not exist. However, it
Autor:
Paul Lorigan, Rohit Thakur, Miles C. Andrews, Kate Hogan, Piyushkumar A. Mundra, Richard Marais, Martin G. Cook, Kang Zeng, Louis Boon, Antonia Banyard, Nathalie Dhomen, Matthew Smith, Jennifer A. Wargo, Jonathan Greenall, Elena Galvani, Garry Ashton, A. Mandal, Beth A. Helmink, Pablo Garcia-Martinez, Gabriela Gremel, Christopher P. E. Chester, Sara Valpione
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatme
Autor:
Jianjun Gao, Hao Zhao, Rebecca S. S. Tidwell, Emily Z. Keung, Yuji Miura, Salahaldin A. Tahir, Sumit K. Subudhi, Hussein Abdul-Hassan Tawbi, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Jorge Blando
Publikováno v:
Proceedings of the National Academy of Sciences. 116:22246-22251
Immune checkpoint (IC) therapy provides substantial benefits to cancer patients but can also cause distinctive toxicities termed immune-related adverse events (irAEs). Biomarkers to predict toxicities will be necessary to improve management of patien
Autor:
Timothy F. Cloughesy, Yue Lu, James R. Heath, Frances Chow, Richard Everson, Robert M. Prins, Michael T. Tetzlaff, Jennifer A. Wargo, Alphonsus H. C. Ng, Rohit Thakur, Beth A. Helmink
Publikováno v:
Nature communications, vol 12, iss 1
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f007076811a2b3d9771fde1cbbaa92af
https://escholarship.org/uc/item/3bm882sp
https://escholarship.org/uc/item/3bm882sp
Autor:
Adi Nagler, Kuoyuan Cheng, Alexandre Reuben, Kun Wang, Deborah Nejman, Mitchell P. Levesque, Maya Lotan-Pompan, Ron Rotkopf, Chantale Bernatchez, Adina Weinberger, Jessica Galloway-Peña, Ronen Levy, Sarah B. Johnson, Scott N. Peterson, Jennifer A. Wargo, Jacob Schachter, Yardena Samuels, Aviyah Peri, Polina Greenberg, Tali Dadosh, Leandro C. Hermida, Ofra Golani, Eilon Barnea, Noam Shental, Naama Geva-Zatorsky, Yishai Levin, Lior Roitman, Garold Fuks, David J. Adams, Eran Segal, Leore T. Geller, William C Shropshire, Cara Haymaker, Raya Eilam, Ravid Straussman, Michal Lotem, Kevin Vervier, Chaya Barbolin, Neerupma Bhardwaj, Smadar Levin-Zaidman, Arie Admon, Yuval Bussi, Gal Yagel, Michal Alon, Eytan Ruppin, Gil Benedek, Steven L. C. Ketelaars, Shelly Kalaora, Trevor D. Lawley, Sophie Trabish, Reetakshi Arora, Pia Kvistborg, Michal J. Besser
Publikováno v:
Nature
A variety of species of bacteria are known to colonize human tumours1–11, proliferate within them and modulate immune function, which ultimately affects the survival of patients with cancer and their responses to treatment12–14. However, it is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc4e3a8e26499995bc3104dc84f785da
https://europepmc.org/articles/PMC9717498/
https://europepmc.org/articles/PMC9717498/
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of